2220 GMT - Ord Minnett is confident about its buy call on Regis Healthcare ahead of key reforms to accommodation funding on Nov. 1. It expects these reforms to be a material driver of Regis's medium-term earnings. Central to this is room pricing, known to investors as RAD, says analyst Tom Godfrey. "We note that the company's latest advertised prices have increased 19% since December," to now stand at A$638,000, says Ord Minnett. This is well ahead of its estimates. Ord Minnett says this can raise Regis's RAD funding to A$2.2 billion, from A$1.7 billion. (david.winning@wsj.com; @dwinningWSJ)
(END) Dow Jones Newswires
June 15, 2025 18:20 ET (22:20 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.